Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -483,534 | -333,969 | -162,672 | -459,851 | -317,519 |
| Depreciation Amortization | 21,724 | 14,909 | 7,164 | 32,196 | 23,621 |
| Accounts receivable | 13,328 | 8,744 | 6,785 | 7,831 | 9,354 |
| Accounts payable and accrued liabilities | -32,104 | -24,565 | -29,575 | 19,010 | -1,285 |
| Other Working Capital | 48,443 | -51,107 | -55,554 | 138,783 | 117,367 |
| Other Operating Activity | 106,884 | 82,364 | 48,293 | 35,549 | 39,205 |
| Operating Cash Flow | $-325,259 | $-303,624 | $-185,559 | $-226,482 | $-129,257 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -15,918 | -11,165 | -6,579 | -32,180 | -25,568 |
| Net Acquisitions | -87,422 | -87,422 | -87,422 | N/A | N/A |
| Purchase Of Investment | -374,767 | -250,715 | N/A | -756,118 | -508,983 |
| Sale Of Investment | 517,240 | 345,457 | 174,006 | 427,648 | 244,777 |
| Other Investing Activity | -88 | 365 | 172 | 0 | -361 |
| Investing Cash Flow | $39,045 | $-3,480 | $80,177 | $-360,650 | $-290,135 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 122,217 | N/A | N/A | 278,607 | 278,607 |
| Debt Repayment | N/A | N/A | N/A | -19,997 | -19,997 |
| Common Stock Issued | 338,210 | 329,834 | 318,668 | 362,128 | 348,413 |
| Other Financing Activity | -85 | -85 | 0 | 0 | 0 |
| Financing Cash Flow | $460,342 | $329,749 | $318,668 | $620,738 | $607,023 |
| Exchange Rate Effect | -4,110 | -2,811 | -202 | -154 | -418 |
| Beginning Cash Position | 389,115 | 389,115 | 389,115 | 355,663 | 355,663 |
| End Cash Position | 559,133 | 408,949 | 602,199 | 389,115 | 542,876 |
| Net Cash Flow | $170,018 | $19,834 | $213,084 | $33,452 | $187,213 |
| Free Cash Flow | |||||
| Operating Cash Flow | -325,259 | -303,624 | -185,559 | -226,482 | -129,257 |
| Capital Expenditure | -15,918 | -11,165 | -6,579 | -32,180 | -25,568 |
| Free Cash Flow | -341,177 | -314,789 | -192,138 | -258,662 | -154,825 |